136 related articles for article (PubMed ID: 6998373)
1. Cefroxadine (CGP-9000), an orally active cephalosporin.
Yasuda K; Kurashige S; Mitsuhashi S
Antimicrob Agents Chemother; 1980 Jul; 18(1):105-10. PubMed ID: 6998373
[TBL] [Abstract][Full Text] [Related]
2. [Comparative double-blind study of cefroxadine and cephalexin in the treatment of complicated urinary tract infection].
Kamidono S; Harada M; Ishigami J; Takasaki N; Miyazaki S; Furusawa T; Mizunoe Y; Ito K; Momose S; Nakamuta S
Jpn J Antibiot; 1983 Sep; 36(9):2571-94. PubMed ID: 6361324
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of cefroxadine in the field of pediatrics (author's transl)].
Iwai N; Sasaki A; Taneda Y; Inokuma K; Nakamura H
Jpn J Antibiot; 1981 Dec; 34(12):1663-79. PubMed ID: 7334591
[TBL] [Abstract][Full Text] [Related]
4. CGP 9000: a new orally active, broad-spectrum cephalosporin.
Zak O; Vischer WA; Schenk C; Tosch W; Zimmermann W; Regös J; Suter ER; Kradolfer F; Gelzer J
J Antibiot (Tokyo); 1976 Jun; 29(6):653-5. PubMed ID: 950320
[TBL] [Abstract][Full Text] [Related]
5. [Laboratory and clinical studies cefroxadine in pediatric field (author's transl)].
Kawamura Y; Nomura T; Ihara T; Shimizu S; Kamiya H; Sakurai M; Nishi H
Jpn J Antibiot; 1981 Dec; 34(12):1655-62. PubMed ID: 7334590
[TBL] [Abstract][Full Text] [Related]
6. Laboratory studies with BL-S 578 (Cefadroxil) a new broad-spectrum orally active cephalosporin.
Ripa S; Prenna M
Chemotherapy; 1979; 25(1):9-13. PubMed ID: 33784
[TBL] [Abstract][Full Text] [Related]
7. [Laboratory and clinical studies on cefroxadine (author's transl)].
Nishikawa K; Aso K; Miyachi Y; Ogawa A; Yafuso M; Kuno K
Jpn J Antibiot; 1981 Dec; 34(12):1647-54. PubMed ID: 7334589
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of cefroxadine in the field of obstetrics and gynecology].
Okada N; Sugimoto Y; Suno N; Shikato Y
Jpn J Antibiot; 1983 Sep; 36(9):2556-61. PubMed ID: 6655870
[TBL] [Abstract][Full Text] [Related]
9. [Double-blind comparative trial of cefroxadine and cephalexin in the treatment of acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media].
Baba S; Murai K; Kinoshita H; Kawai T; Koyama K; Tsukiyama M; Maruo T; Wada K; Inagaki M; Matsushita T
Jpn J Antibiot; 1983 Sep; 36(9):2595-634. PubMed ID: 6361325
[TBL] [Abstract][Full Text] [Related]
10. [Study on the transfer of cefroxadine to human tears].
Hara J; Tanaka Y; Harino S; Deguchi K
Jpn J Antibiot; 1985 Feb; 38(2):230-4. PubMed ID: 4009946
[TBL] [Abstract][Full Text] [Related]
11. [Laboratory and clinical studies of cefroxadine (author's transl)].
Nishimura T; Tabuki K; Hiromatsu K; Takashima T; Kotani Y
Jpn J Antibiot; 1981 Dec; 34(12):1634-46. PubMed ID: 7334588
[TBL] [Abstract][Full Text] [Related]
12. [Clinical trials of cefroxadine on skin and soft tissue infections in the field of pediatrics (author's transl)].
Motohiro T; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Nishiyama T; Fujimoto T; Nakajima T; Ishimoto K; Tominaga K; Yamashita F; Tomoishi T; Takenaka S; Kamezaki K; Ohyama K; Takasaki K; Oki S; Yoshinaga Y; Nagai T; Kawano N; Toyoda J; Shimohida T
Jpn J Antibiot; 1981 Dec; 34(12):1732-46. PubMed ID: 7038190
[TBL] [Abstract][Full Text] [Related]
13. [In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)].
Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Oda S; Matsumoto Y; Ikegami R; Sato K; Fukumoto T
Jpn J Antibiot; 1985 Oct; 38(10):2797-808. PubMed ID: 3878415
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activity of KT3777, a new orally active carbacephem.
Sato K; Okachi R; Matsukuma I; Mochida K; Hirata T
J Antibiot (Tokyo); 1989 Dec; 42(12):1844-53. PubMed ID: 2621166
[TBL] [Abstract][Full Text] [Related]
15. [Experimental and clinical evaluation of cefroxadine in the field of obstetrics and gynecology].
Cho N; Araki H; Ishikawa T; Kunii K; Fukunaga K; Deguchi K
Jpn J Antibiot; 1983 Sep; 36(9):2535-48. PubMed ID: 6655868
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effect of cefroxadine on surgical infections].
Aikawa T; Noguchi S; Fujimoto N; Mizushima H; Shibata N; Tomita N; Horii A
Jpn J Antibiot; 1983 Sep; 36(9):2521-8. PubMed ID: 6686263
[TBL] [Abstract][Full Text] [Related]
17. [Influence of cefroxadine dry syrup on intestinal bacterial flora].
Iwata S; Yokota T; Kusumoto Y; Shiro H; Sato Y; Akita H; Nanri S; Oikawa T; Kusano S; Sunakawa K
Jpn J Antibiot; 1986 Aug; 39(8):1967-74. PubMed ID: 3540337
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of cefroxadine in the field of obstetrics and gynecology].
Motomori R; Takahashi H; Yamamoto J; Yamasaki F
Jpn J Antibiot; 1983 Sep; 36(9):2562-70. PubMed ID: 6655871
[TBL] [Abstract][Full Text] [Related]
19. [Cefroxadine].
Mashimo K
Jpn J Antibiot; 1982 Jun; 35(6):1365-73. PubMed ID: 6752462
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of FK482, a new orally active cephalosporin.
Mine Y; Kamimura T; Watanabe Y; Tawara S; Matsumoto Y; Shibayama F; Kikuchi H; Takaya T; Kuwahara S
J Antibiot (Tokyo); 1988 Dec; 41(12):1873-87. PubMed ID: 3264828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
